Physician profile
Mark C Wiles
NPI 1598772204
$13,985.08
in general payments reported to CMS, 2019-2025
45 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,898 · 2020: $2,016 · 2021: $2,020 · 2022: $2,379 · 2023: $2,336 · 2024: $2,116 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,671.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,507.92 | 2019-2025 | Xarelto, Spravato |
| Abbvie INC. | $1,462.87 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,132.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,080.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $945.89 | 2019-2023 | |
| Pfizer INC. | $873.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $755.55 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $754.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $556.85 | 2019-2023 | Trulance, Xifaxan |
| Shield Therapeutics INC | $508.48 | 2023-2025 | Accrufer |
| Allergan, INC. | $431.39 | 2019-2020 | |
| Amgen INC. | $402.91 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $296.28 | 2019-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $285.12 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $276.03 | 2019-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.